PMC:7795856 / 295-516 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"32","span":{"begin":32,"end":40},"obj":"Disease"},{"id":"33","span":{"begin":41,"end":51},"obj":"Disease"},{"id":"34","span":{"begin":56,"end":62},"obj":"Disease"}],"attributes":[{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D007239"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent d"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":56,"end":62},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"ers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent d"}